Paion's anesthetic enters Ph II trial
German biopharmaceutical company Paion AG has commenced a Phase II study with CNS 7056, its new short-acting intravenous anesthetic/sedative. The study will enroll 100 patients undergoing diagnostic endoscopy of the upper gastrointestinal tract.
The randomized, double-blind trial will assess three doses of CNS 7056 compared with midazolam in 100 patients undergoing a diagnostic endoscopy of the upper gastrointestinal tract. The study is being conducted in multiple sites in the USA. It is designed to evaluate the safety of CNS 7056 and the success of the sedation, as well as the time to full recovery and discharge, in comparison to the gold-standard agent midazolam, which is the active ingredient in Roche's Versed/Dormicum.
The study is expected to complete before the end of the year. A successful proof-of-concept Phase I trial of CNS 7056 reported results in January.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze